Development of new treatment strategies for HIV -1 infection
| Project/Area Number |
24591486
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | Showa Pharmaceutical University |
|---|
Principal Investigator |
HAMADA Koichi 昭和薬科大学, 薬学部, 助教 (00343070)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | ＨＩＶ－１ / 潜伏感染 / ＰＩ３Ｋ／ＰＴＥＮ / HIV |
|---|
| Outline of Final Research Achievements |
The presence of latent vial infection has prevented the eradication of human immunodeficiency virus (HIV) from infected patients successfully treated with anti-retroviral therapy. Combination antiretroviral therapy (cART) can effectively suppress HIV-1 replication, but the latent viral reservoir is impervious to cART and represents a major barrier to curing HIV-1 infection.
PI3K/PTEN/GSK-3β pathway is a critical role for cell proliferation and survival. In this study, we identified that PI3K/PTEN/GSK-3β pathway is necessary to HIV infection and reactivation.
|
Report
(4 results)
Research Products
(1 results)
